Abstract
Intravenous gene transfer using recombinant retroviruses tends to suffer from a low infectious viral titer when conducted in vivo. This is, in part, caused by complement-mediated proteolytic inactivation of the retrovirus in human serum. However, if the retroviruses were directly injected into the brain, they might not be inactivated. Supernatant from amphotropic retrovirus-producing cells harboring the BAG vectors was incubated with sera or cerebrospinal fluid (CSF) of patients with gliomas or unrelated disorders. The retroviruses were severely inactivated in sera. However, no such inactivation was noted in CSF or fluid from the tumor bed of glioma patients. These data suggest that gene transfer using recombinant retroviruses could be done into the cavity after removal of the tumor in glioma patients.
MeSH terms
-
3T3 Cells
-
Adult
-
Animals
-
Astrocytoma / blood
-
Astrocytoma / cerebrospinal fluid
-
Astrocytoma / chemistry
-
Blood Physiological Phenomena*
-
Body Fluids / physiology
-
Brain Neoplasms / blood
-
Brain Neoplasms / cerebrospinal fluid
-
Brain Neoplasms / chemistry*
-
Cerebrospinal Fluid / physiology
-
Feasibility Studies
-
Female
-
Genes, Reporter
-
Genetic Therapy / methods*
-
Genetic Vectors / genetics
-
Genetic Vectors / physiology*
-
Glioblastoma / blood
-
Glioblastoma / cerebrospinal fluid
-
Glioblastoma / chemistry
-
Glioma / blood
-
Glioma / cerebrospinal fluid
-
Glioma / chemistry*
-
Humans
-
Male
-
Mice
-
Middle Aged
-
Neuroma, Acoustic / blood
-
Neuroma, Acoustic / cerebrospinal fluid
-
Recombinant Fusion Proteins / analysis
-
Retroviridae / genetics
-
Retroviridae / physiology*
-
Trigeminal Neuralgia / blood
-
Trigeminal Neuralgia / cerebrospinal fluid
-
Virus Replication*
-
beta-Galactosidase / analysis
-
beta-Galactosidase / genetics
Substances
-
Recombinant Fusion Proteins
-
beta-Galactosidase